SEC 13F Intelligence

Managers / Q3 2021 · view latest →

HighVista Strategies LLC

CIK 0001335325 · 200 CLARENDON STREET, 50TH FLOOR, BOSTON, MA, 02116 · 617-406-6500

Reported Value
$151M
Q3 2021
Positions
127
Filings on Record
30
2019–present window
Filed
Nov 15, 2021
original filing

Summary

Highvista Strategies LLC reported $151M in U.S.-listed holdings across 127 positions for Q3 2021.

The portfolio is heavily concentrated: DELL alone accounts for 24.5% of reported value.

Compared with Q2 2021, the fund opened 39 new positions and exited 28.

Portfolio Metrics

Turnover
+29.9%
vs prior filed quarter
Top-10 Concentration
+48.8%
share of reported value
Largest Position
+24.5%
Dell Technologies
New / Exited
39 / 28
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $116MQ4 ’18Q1 ’19: $123MQ2 ’19: $195MQ3 ’19: $147MQ4 ’19: $132MQ4 ’19Q1 ’20: $108MQ2 ’20: $121MQ3 ’20: $137MQ4 ’20: $157MQ4 ’20Q1 ’21: $135MQ2 ’21: $141MQ3 ’21: $151MQ4 ’21: $126MQ4 ’21Q1 ’22: $157MQ2 ’22: $166MQ3 ’22: $175MQ4 ’22: $168MQ4 ’22Q1 ’23: $123MQ2 ’23: $219MQ3 ’23: $216MQ4 ’23: $276MQ4 ’23Q1 ’24: $280MQ2 ’24: $274MQ3 ’24: $290MQ4 ’24: $269MQ4 ’24Q1 ’25: $260MQ2 ’25: $272MQ3 ’25: $408MQ4 ’25: $388MQ4 ’25Q1 ’26: $362Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 78.2%Other: 14.5%ADR: 4.6%ETP: 2.6%REIT: 0.1%
  • Common Stock · 78.2% · $118M
  • Other · 14.5% · $22M
  • ADR · 4.6% · $7M
  • ETP · 2.6% · $4M
  • REIT · 0.1% · $100,000

Quarter-over-Quarter Changes full breakdown →

vs Q2 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
CPNGCOUPANG INCNEW+256.3K256.3K+$7M$7M
PPD INCNEW+74.9K74.9K+$4M$4M
KSUEURKANSAS CITY SOUTHERNNEW+12.9K12.9K+$3M$3M
CHNGUSDCHANGE HEALTHCARE INCNEW+162.1K162.1K+$3M$3M
FIVNFIVE9 INCNEW+17.4K17.4K+$3M$3M
ARNAEURARENA PHARMACEUTICALS INCNEW+23.9K23.9K+$1M$1M
RNAGBPAVIDITY BIOSCIENCES INCNEW+56.9K56.9K+$1M$1M
ZNTLZENTALIS PHARMACEUTICALS INCNEW+20.6K20.6K+$1M$1M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2021

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1DELLDELL TECHNOLOGIES INChistory →CL C24.47%$37M355.4K
2CPNGCOUPANG INChistory →CL A4.72%$7M256.3K
3MSD ACQUISITION CORPUNIT 03/25/20263.31%$5M500.0K
4IHS MARKIT LTDSHS2.53%$4M32.7K
5XLNXEURXILINX INChistory →COM2.42%$4M24.2K
6NUANEURNUANCE COMMUNICATIONS INChistory →COM2.36%$4M64.8K
7PPD INCCOM2.32%$4M74.9K
8KSUEURKANSAS CITY SOUTHERNhistory →COM NEW2.31%$3M12.9K
9CHNGUSDCHANGE HEALTHCARE INChistory →COM2.25%$3M162.1K
10ISHARES TRMSCI INDIA SM CP2.08%$3M52.3K
11FIVNFIVE9 INChistory →COM1.84%$3M17.4K
12BABAALIBABA GROUP HLDG LTDhistory →SPONSORED ADS1.80%$3M18.4K
13CATALYST PARTNRS ACQUISITN CUNIT 99/99/99991.30%$2M200.0K
14XLRNACCELERON PHARMA INChistory →COM1.11%$2M9.8K
15ACRSACLARIS THERAPEUTICS INChistory →COM1.11%$2M93.0K
16ONCBEIGENE LTDhistory →SPONSORED ADR1.09%$2M4.5K
17ASCENDIS PHARMA A/SSPONSORED ADR1.03%$2M9.8K
18TCE2CELLDEX THERAPEUTICS INC NEWhistory →COM NEW1.02%$2M28.5K
19MRTXEURMIRATI THERAPEUTICS INCCOM0.99%$2M8.5K
20ARNAEURARENA PHARMACEUTICALS INCCOM NEW0.94%$1M23.9K
21KNTEUSDKINNATE BIOPHARMA INCCOM0.93%$1M60.9K
22RNAGBPAVIDITY BIOSCIENCES INCCOM0.93%$1M56.9K
23IOVAIOVANCE BIOTHERAPEUTICS INCCOM0.92%$1M56.3K
24TVTXTRAVERE THERAPEUTICS INCCOM0.91%$1M56.7K
25ZNTLZENTALIS PHARMACEUTICALS INCCOM0.91%$1M20.6K
26CURIS INCCOM NEW0.89%$1M172.4K
27KURAKURA ONCOLOGY INCCOM0.88%$1M70.9K
28CCCCC4 THERAPEUTICS INCCOM STK0.87%$1M29.3K
292655787DBLUEPRINT MEDICINES CORPCOM0.86%$1M12.7K
30INSTIL BIO INCCOM0.85%$1M72.1K
31INVITAE CORPCOM0.85%$1M45.0K
32NBIXNEUROCRINE BIOSCIENCES INCCOM0.84%$1M13.2K
33HORIZON THERAPEUTICS PUB LSHS0.82%$1M11.3K
34NTRANATERA INCCOM0.81%$1M11.0K
35RCKTROCKET PHARMACEUTICALS INCCOM0.80%$1M40.7K
36STOKSTOKE THERAPEUTICS INCCOM0.80%$1M47.6K
37VTGNUSDVISTAGEN THERAPEUTICS INCCOM NEW0.79%$1M438.2K
38RLAYRELAY THERAPEUTICS INCCOM0.79%$1M37.7K
39PMVPPMV PHARMACEUTICALS INCCOM0.78%$1M39.8K
40ALNYALNYLAM PHARMACEUTICALS INCCOM0.77%$1M6.2K
41BBIOBRIDGEBIO PHARMA INCCOM0.76%$1M24.7K
42MORFUSDMORPHIC HLDG INCCOM0.76%$1M20.3K
43EPIEURESSA PHARMA INCCOM NEW0.76%$1M143.6K
44XENEXENON PHARMACEUTICALS INCCOM0.76%$1M75.0K
45MGNXMACROGENICS INCCOM0.75%$1M54.0K
46ARGXARGENX SESPONSORED ADR0.74%$1M3.7K
47UTHUNITED THERAPEUTICS CORP DELCOM0.72%$1M5.9K
48AM6AMICUS THERAPEUTICS INCCOM0.72%$1M113.4K
49NVV1NOVAVAX INCCOM NEW0.68%$1M5.0K
50OPHTEURIVERIC BIO INCCOM0.68%$1M63.1K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$362M156May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$388M145Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$408M148Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$272M146Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$260M148May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$269M137Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$290M142Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$274M138Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$280M131May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$276M126Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$216M132Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$219M134Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$123M108May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$168M105Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$175M113Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$166M110Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$157M86May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$126M69Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$151M127Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$141M116Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$135M125May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$157M117Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$137M113Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$121M100Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$108M65May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$132M119Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$147M126Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$195M108Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$123M112May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$116M113Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.